American Bio Medica Corp. (ABMC)
| Market Cap | 6.82M |
| Revenue (ttm) | 4.25M |
| Net Income (ttm) | -804,000 |
| Shares Out | 35.96M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $0.1799 |
| Previous Close | $0.1900 |
| Change ($) | -0.0101 |
| Change (%) | -5.32% |
| Day's Open | 0.1722 |
| Day's Range | 0.1710 - 0.1897 |
| Day's Volume | 462,317 |
| 52-Week Range | 0.0575 - 1.24 |
News
There are no news available yet.
About ABMC
American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detect... [Read more...]
| Industry Diagnostics & Research | IPO Date Dec 24, 1997 |
| CEO Melissa A. Waterhouse | Employees 42 |
| Stock Exchange OTCMKTS | Ticker Symbol ABMC |
Financial Performance
In 2019, ABMC's revenue was $3.66 million, a decrease of -5.60% compared to the previous year's $3.87 million. Losses were -$681,000, -33.75% less than in 2018.